Extraocular retinoblastoma in Saudi arabia

Susan H. Senft, Thomas Johnson, Amin M. Nasr

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Advanced retinoblastoma has a reported 95% mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7% with extraocular disease. Of these, 26 (44.9% manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36% were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8% (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100% mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalOrbit
Volume12
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Retinoblastoma
Saudi Arabia
Radiotherapy
Neoplasms
Mortality
Vincristine
Therapeutics
Doxorubicin
Cyclophosphamide
Disease Progression
Age Groups
Drug Therapy
Survival

Keywords

  • Extraocular neoplasm
  • Malignant ocular tumor
  • Orbital invasion
  • Retinoblastoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Extraocular retinoblastoma in Saudi arabia. / Senft, Susan H.; Johnson, Thomas; Nasr, Amin M.

In: Orbit, Vol. 12, No. 1, 1993, p. 19-26.

Research output: Contribution to journalArticle

Senft, Susan H. ; Johnson, Thomas ; Nasr, Amin M. / Extraocular retinoblastoma in Saudi arabia. In: Orbit. 1993 ; Vol. 12, No. 1. pp. 19-26.
@article{472ca66d3faa480280d98ceb263ef0d3,
title = "Extraocular retinoblastoma in Saudi arabia",
abstract = "Advanced retinoblastoma has a reported 95{\%} mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7{\%} with extraocular disease. Of these, 26 (44.9{\%} manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36{\%} were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8{\%} (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100{\%} mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.",
keywords = "Extraocular neoplasm, Malignant ocular tumor, Orbital invasion, Retinoblastoma",
author = "Senft, {Susan H.} and Thomas Johnson and Nasr, {Amin M.}",
year = "1993",
doi = "10.3109/01676839309029879",
language = "English (US)",
volume = "12",
pages = "19--26",
journal = "Orbit",
issn = "0167-6830",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Extraocular retinoblastoma in Saudi arabia

AU - Senft, Susan H.

AU - Johnson, Thomas

AU - Nasr, Amin M.

PY - 1993

Y1 - 1993

N2 - Advanced retinoblastoma has a reported 95% mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7% with extraocular disease. Of these, 26 (44.9% manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36% were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8% (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100% mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.

AB - Advanced retinoblastoma has a reported 95% mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7% with extraocular disease. Of these, 26 (44.9% manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36% were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8% (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100% mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.

KW - Extraocular neoplasm

KW - Malignant ocular tumor

KW - Orbital invasion

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=0027238428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027238428&partnerID=8YFLogxK

U2 - 10.3109/01676839309029879

DO - 10.3109/01676839309029879

M3 - Article

VL - 12

SP - 19

EP - 26

JO - Orbit

JF - Orbit

SN - 0167-6830

IS - 1

ER -